Study Group: Cosmetic Dermatologists
Council Members in this Study Group: 349
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Sunil DhawanClinical Assistant Professor of Dermatology
STANFORD UNIVERSITY
Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed...
- Brian Lester
Dermatologist
Brian W Lester, MDBrian Lester, MD, is a Dermatologist in private practice in Massachusetts. His interests include clinical dermatology, cosmetic dermatology, dermatopathology, and dermatologic pharmaceuticals. He has experience with clinical trials involving a variety...
Michele PauporteDermatologist
JUVA SKIN LASER CENTER INCMichele Pauporte, MD, is a dermatologist at Juva Skin and Laser Center, in New York City. Dr. Pauporte's areas of expertise include cosmetic procedures and the treatment of skin cancers, including Mohs micrographic surgery and reconstructive surgery....
- Michael Bain
Plastic and Reconstructive Physician
Michael A Bain, MDMichael Bain, MD, MS, is a Plastic and Reconstructive Physician in private practice based in Southern California. He has experience in all areas of plastic and reconstructive surgery including bariatric, breast, cosmetic, and reconstructive surgery. Dr....
- Robert Koppel
Owner
ROBERT KOPPELRobert Koppel, MD, is a Dermatologist in private practice in Metairie, Louisiana. He also serves as an Assistant Clinical Professor of Dermatology at the Tulane University School of Medicine. Dr. Koppel is knowledgeable of all aspects of medical, surgical,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 19, 2009
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Presta Trial shows good results for Enbrel
October 14, 2009
New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com
This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy, and more convenient dosing regimens. Both will be doing similar studies.
-
Will the withdrawl of Efalizumab effect the biologic market?
April 15, 2009
Efalizumab withdrawn from US Market | www.medscape.com
This article is important in that the withdrawal of efalizumab by Genentech was appropriate in view of its serious side effect of progressive multifocal leukoencephalopathy (PML). This biologic agent was already declining in usage because of its other side effects, and the presence of other strong competitors with equal or higher efficacy and less side effects. This was to be compounded by the impending release of ustekinumab
-
Aurobindo terbinafine approval- what effect will this have?
January 21, 2009
Aurobindo Pharma gets approval for Terbinafine Tablets | myiris.com
This article is important in that it confirms another terbinafine competitor to the Novartis Lamisil brand is being released. The majority of terbinafine prescriptions in North America are generic. The market for this product will be good at least until more effective oral or topical agents are released. The majority of the prescriptions are for onychomycosis (toenail fungus). The newer products will be released in 3-4 years, at which time the market for terbinafine will shrink significantly.
-
Filler Warnings- Are They Necessary?
November 24, 2008
FDA Faults Wrinkle Fillers Over Warnings | online.wsj.com
This article is important in that it discusses a rare but known side effect of filler injections- reactions to these agents. These reactions include allergies, infections, etc. The incidence is low- approximately 1000 cases out of 1.5 million injections. The majority of these reactions were not serious. The various fillers were not differentiated, but it is likely that the hyaluronic acid fillers like Restylane/Perlane/Juvaderm will have the lowest incidence as they are the closest to human hyaluronic acid that is present in the skin. This article and the FDA warning is unlikely to effect the use or sales of these fillers.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- President
- Director
- Partner
- Physician - Division Head